Gene · 27329
Papers2,231
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 2,231
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Angiopoietin-like protein inhibitors: Promising agents for the treatment of familial hypercholesterolemia and atherogenic dyslipidemia. | Atherosclerosis | 2025 | 40344904 | PubTator, text mining | PubMed |
| Angiopoietin-Like Protein Family-Mediated Functions in Modulating Triglyceride Metabolism and Related Metabolic Diseases. | Front Biosci (Landmark Ed) | 2025 | 40302331 | PubTator, text mining | PubMed |
| News in cardiovascular pharmacotherapy from the ACC.25 Meeting. | Eur Heart J Cardiovasc Pharmacother | 2025 | 40300823 | PubTator, text mining | PubMed |
| Treatment of Homozygous Familial Hypercholesterolemia. | JACC Adv | 2025 | 40288084 | PubTator, text mining | PubMed |
| Genetics of remnant cholesterol. | Curr Opin Lipidol | 2025 | 40277396 | PubTator, text mining | PubMed |
| Novel Therapeutics for Familial Chylomicronemia Syndrome. | Curr Atheroscler Rep | 2025 | 40257687 | PubTator, text mining | PubMed |
| The significance of ANGPTL3 and ANGPTL4 proteins in the development of dyslipidemia in Type 2 diabetes mellitus. | J Family Med Prim Care | 2025 | 40256107 | PubTator, text mining | PubMed |
| Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial. | Lancet | 2025 | 40179932 | PubTator, text mining | PubMed |
| Therapy for mixed dyslipidaemia through ANGPTL3 inhibition. | Lancet | 2025 | 40179931 | PubTator, text mining | PubMed |
| Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia: A Phase 2 Study. | J Am Coll Cardiol | 2025 | 40167414 | PubTator, text mining | PubMed |
| Beyond LDL: Targeting ANGPTL3 to Reduce Residual Cardiovascular Risk. | J Am Coll Cardiol | 2025 | 40167412 | PubTator, text mining | PubMed |
| Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects. | Expert Rev Mol Med | 2025 | 40160040 | PubTator, text mining | PubMed |
| Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies. | J Am Coll Cardiol | 2025 | 40158211 | PubTator, text mining | PubMed |
| ANGPTL3/8 is an atypical unfoldase that regulates intravascular lipolysis by catalyzing unfolding of lipoprotein lipase. | Proc Natl Acad Sci U S A | 2025 | 40112106 | PubTator, text mining | PubMed |
| Depletion of Hepatic SREBP2 Protects Against Hypercholesterolemia and Atherosclerosis through the ANGPTL3-LPL Axis. | Adv Sci (Weinh) | 2025 | 40106311 | PubTator, text mining | PubMed |
| Comparison of Model-Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial Hypercholesterolemia. | CPT Pharmacometrics Syst Pharmacol | 2025 | 40095766 | PubTator, text mining | PubMed |
| Population Pharmacokinetics and Exposure-Response Modeling for Evinacumab in Children, Adolescents, and Adults With Homozygous Familial Hypercholesterolemia. | CPT Pharmacometrics Syst Pharmacol | 2025 | 40095399 | PubTator, text mining | PubMed |
| RNA Therapies in Cardio-Kidney-Metabolic Syndrome: Advancing Disease Management. | J Cardiovasc Transl Res | 2025 | 40080261 | PubTator, text mining | PubMed |
| Evaluating the Cardiometabolic Efficacy and Safety of Lipoprotein Lipase Pathway Targets in Combination With Approved Lipid-Lowering Targets: A Drug Target Mendelian Randomization Study. | Circ Genom Precis Med | 2025 | 40052268 | PubTator, text mining | PubMed |
| Treatment With Evinacumab Links a New Pathogenic Variant in the LPL Gene to Persistent Chylomicronemia. | J Endocr Soc | 2025 | 40046103 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/27329/papers?page=12